Finance Watch: Erasca Raises $200m As VC Mega-Rounds Continue
Executive Summary
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.
You may also be interested in...
Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Need a specific report? 1000+ reports available
Buy Reports